CAR-T Therapy
In a recent breakthrough for cancer treatment, a team of researchers has developed HSP-CAR30, a novel CAR-T cell therapy that has shown remarkable efficacy in treating relapsed or refractory CD30-positive lymphomas—diseases notoriously resistant to conventional therapies.
Key Features of the Innovation
- Targets the CD30 protein, commonly found in Hodgkin lymphoma and CD30-positive T-cell lymphomas.
- Demonstrated 100% overall response rate in Phase I clinical trials—an extraordinary result for heavily pre-treated patients.
- Achieved 50% complete remission, with disease becoming undetectable through imaging and clinical evaluation.
|
What is CAR T Cell Therapy?
|
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 India Successfully Test-Fires Prithvi-II, Agni-I and Akash Prime Missiles
- 2 Indian Navy Commissions ‘INS Nistar’
- 3 Research in Science & Tech in India
- 4 RDSNS Breakthrough Could Revolutionize Magnetometry
- 5 Vera C Rubin Observatory
- 6 WHO Recommends Injectable Lenacapavir for HIV Prevention
- 7 NASA Launches Sounding Rocket to Study Sun’s Chromosphere
- 8 Indian Navy Launches Final ASW Shallow Water Craft ‘Ajay’
- 9 Black Hole Merger Detection
- 10 Indigenous Pollution Control Vessel ‘Samudra Prachet’
